search
Back to results

Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery

Primary Purpose

Pain, Postoperative

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Bupivacaine Collagen Sponge
Placebo
Sponsored by
Innocoll
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring Gastrointestinal surgery, Post operative pain

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must be a man or woman who is ≥ 18 and ≤ 75 years of age.
  • Has a body mass index (BMI) > 19 and < 40 kg/m2.
  • Has a planned elective surgery that requires a vertical or transverse abdominal incision (including but not limited to abdominal aortic aneurysm repair, cholecystectomy and simple bowel resection) to be performed according to standard surgical technique under general anesthesia.
  • Has a risk classification of I, II or III according to the American Society of Anesthesiologists (ASA)
  • If female, is nonpregnant (negative pregnancy test at Screening and Day 0 before surgery) and nonlactating.
  • If female, is either not of childbearing potential or practicing a defined medically acceptable method of birth control and agrees to continue with the regimen throughout the study.
  • Is free of other physical or mental conditions that, in the opinion of the Investigator, may confound quantification of postoperative pain resulting from the surgery.
  • Has the ability and willingness to comply with the study procedures and the use of the pain scales; is deemed capable of operating a PCA device; and is able to communicate meaningfully with the study staff.
  • Must voluntarily sign and date an informed consent form (ICF) that is approved by an IRB prior to the conduct of any study specific procedures.
  • Must be able to fluently speak and understand English and be able to provide meaningful written informed consent for the study.

Exclusion Criteria:

  • Has known hypersensitivity to amide local anesthetics, opioids or bovine products, or to inactive ingredients of the test article.
  • Has 1 of the following surgical procedures planned: total abdominal hysterectomy, omentectomy or surgical procedure for staging cancer.
  • Requires the use of Seprafilm® or other absorbable adhesion barriers for the GI surgery.

Requires any additional surgical procedures either related or unrelated to the GI surgery during the same hospitalization.

  • Is required to receive neuraxial (spinal or epidural) opioid analgesics during the study.
  • Has cardiac arrhythmia or atrioventricular (AV) conduction disorders.
  • Concomitantly uses antiarrhythmics (eg, amiodarone), propranolol or strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice).
  • Has used long acting analgesics within 24 hours of surgery. Short acting analgesics such as acetaminophen may be used on the day of surgery but are subject to preoperative restrictions for oral intake.
  • Has used aspirin or aspirin containing products within 7 days of surgery. Aspirin at a dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on a stable dose regimen for ≥ 30 days prior to Screening.
  • Has undergone another major surgery within 3 months of the GI surgery.
  • Has known or suspected history of alcohol or drug abuse or misuse within 3 years of Screening or evidence of tolerance or physical dependency on opioid analgesics or sedative hypnotic medications.

Sites / Locations

  • Albany Medical Center Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.

Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.

Outcomes

Primary Outcome Measures

The Total Amount of Opioid Rescue Analgesia Used
Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.

Secondary Outcome Measures

The Total Amount of Opioid Rescue Analgesia Used
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
The Total Amount of Opioid Rescue Analgesia Used
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Pain Intensity Rating on the Visual Analogue Scale (VAS)
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Pain Intensity Rating on a 4-point Scale
Study Terminated Early - Secondary end point not measured - not done
Pain Relief Rating on a 5-point Scale
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Patient Global Evaluation of Study Treatment on a 5-point Scale
Study Terminated Early - Secondary end point not measured - not done
Time to First Use of Opioid Rescue Analgesia
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Pharmacokinetic Parameters
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
The Incidence of Treatment-emergent Adverse Events
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Changes in Vital Sign Measurements
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.

Full Information

First Posted
April 15, 2008
Last Updated
November 2, 2020
Sponsor
Innocoll
Collaborators
Premier Research Group plc
search

1. Study Identification

Unique Protocol Identification Number
NCT00661466
Brief Title
Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery
Official Title
A Phase II, Randomized, Single-dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx Bupivacaine Implant in Patients After Gastrointestinal Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Terminated
Why Stopped
Business decision
Study Start Date
July 24, 2008 (undefined)
Primary Completion Date
January 10, 2009 (Actual)
Study Completion Date
February 10, 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Innocoll
Collaborators
Premier Research Group plc

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether the CollaRx Bupivacaine Implant (bupivacaine sponge) is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 24 hours after gastrointestinal (GI) surgery.
Detailed Description
Gastrointestinal (GI) surgery encompasses a range of surgical procedures that involve abdominal incision. Gastrointestinal surgery may be performed to treat an abdominal aortic aneurysm, ulcerative colitis, Crohn's disease, gallbladder disease, bile duct disease and morbid obesity. Although less invasive laparoscopic procedures are performed when warranted, open abdominal surgery is required for certain indications and for more complicated or advanced cases. Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile. Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes for cow tendons and contains bupivacaine. When inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. The high levels of bupivacaine at the surgical site may result in less pain for several days after surgery. This study will compare the amount of narcotic pain medication required after surgery in patients who receive the CollaRx Bupivacaine implant or a plain collagen sponge.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative
Keywords
Gastrointestinal surgery, Post operative pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine Collagen Sponge
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo
Primary Outcome Measure Information:
Title
The Total Amount of Opioid Rescue Analgesia Used
Description
Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Time Frame
0 to 24 hours postoperatively
Secondary Outcome Measure Information:
Title
The Total Amount of Opioid Rescue Analgesia Used
Description
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Time Frame
0 to 48 hours postoperatively
Title
The Total Amount of Opioid Rescue Analgesia Used
Description
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Time Frame
0 to 72 hours postoperatively
Title
Pain Intensity Rating on the Visual Analogue Scale (VAS)
Description
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Time Frame
1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0
Title
Pain Intensity Rating on a 4-point Scale
Description
Study Terminated Early - Secondary end point not measured - not done
Time Frame
At 1, 1.5, 2, 3, 6, 9, 12, 18, 24, 36, 48 and 72 hours postoperatively
Title
Pain Relief Rating on a 5-point Scale
Description
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Time Frame
At 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0
Title
Patient Global Evaluation of Study Treatment on a 5-point Scale
Description
Study Terminated Early - Secondary end point not measured - not done
Time Frame
At 72 hours after time 0
Title
Time to First Use of Opioid Rescue Analgesia
Description
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Time Frame
actual time from time 0
Title
Pharmacokinetic Parameters
Description
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Time Frame
30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48 and 72 hours postoperatively
Title
The Incidence of Treatment-emergent Adverse Events
Description
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Time Frame
Through 30 days after surgery
Title
Changes in Vital Sign Measurements
Description
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment. Target recruitment not met. Primary outcome not measured - planned statistical analyses was not performed.
Time Frame
Through 72 hours post insertion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must be a man or woman who is ≥ 18 and ≤ 75 years of age. Has a body mass index (BMI) > 19 and < 40 kg/m2. Has a planned elective surgery that requires a vertical or transverse abdominal incision (including but not limited to abdominal aortic aneurysm repair, cholecystectomy and simple bowel resection) to be performed according to standard surgical technique under general anesthesia. Has a risk classification of I, II or III according to the American Society of Anesthesiologists (ASA) If female, is nonpregnant (negative pregnancy test at Screening and Day 0 before surgery) and nonlactating. If female, is either not of childbearing potential or practicing a defined medically acceptable method of birth control and agrees to continue with the regimen throughout the study. Is free of other physical or mental conditions that, in the opinion of the Investigator, may confound quantification of postoperative pain resulting from the surgery. Has the ability and willingness to comply with the study procedures and the use of the pain scales; is deemed capable of operating a PCA device; and is able to communicate meaningfully with the study staff. Must voluntarily sign and date an informed consent form (ICF) that is approved by an IRB prior to the conduct of any study specific procedures. Must be able to fluently speak and understand English and be able to provide meaningful written informed consent for the study. Exclusion Criteria: Has known hypersensitivity to amide local anesthetics, opioids or bovine products, or to inactive ingredients of the test article. Has 1 of the following surgical procedures planned: total abdominal hysterectomy, omentectomy or surgical procedure for staging cancer. Requires the use of Seprafilm® or other absorbable adhesion barriers for the GI surgery. Requires any additional surgical procedures either related or unrelated to the GI surgery during the same hospitalization. Is required to receive neuraxial (spinal or epidural) opioid analgesics during the study. Has cardiac arrhythmia or atrioventricular (AV) conduction disorders. Concomitantly uses antiarrhythmics (eg, amiodarone), propranolol or strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice). Has used long acting analgesics within 24 hours of surgery. Short acting analgesics such as acetaminophen may be used on the day of surgery but are subject to preoperative restrictions for oral intake. Has used aspirin or aspirin containing products within 7 days of surgery. Aspirin at a dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on a stable dose regimen for ≥ 30 days prior to Screening. Has undergone another major surgery within 3 months of the GI surgery. Has known or suspected history of alcohol or drug abuse or misuse within 3 years of Screening or evidence of tolerance or physical dependency on opioid analgesics or sedative hypnotic medications.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Prior
Organizational Affiliation
Innocoll
Official's Role
Study Director
Facility Information:
Facility Name
Albany Medical Center Hospital
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery

We'll reach out to this number within 24 hrs